Company · CIK 0001501756 · SIC 2836 — Biological Products, (No Diagnostic Substances)
Adverum Biotechnologies, Inc. · ADVM
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 15, 2018 AForm 4 → | Jun 18, 4:39 pm EDT | Mehdi GasmiChief Science & Tech Officer | 88,496 | — | — | 387,031 | — | plan? |
| Jun 15, 2018 AForm 4 → | Jun 18, 4:38 pm EDT | Jennifer C. ChengGeneral Counsel | 11,150 | — | — | 118,863 | — | plan? |
| Jun 15, 2018 AForm 4 → | Jun 18, 4:37 pm EDT | Leone D PattersonSVP, CFO, Interim Pres and CEO | 88,496 | — | — | 268,496 | — | plan? |
| Sep 7, 2017 AForm 4 → | Sep 8, 6:40 pm EDT | Eric G CarterDirector | 48,000 | — | — | 48,000 | — | plan? |
| Jun 19, 2017 AForm 4 → | Jun 21, 6:11 pm EDT | Athena CountouriotisSVP, Chief Medical Officer | 150,000 | — | — | 150,000 | — | plan? |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:13 pm EDT | Mitchell H. FinerDirector | 22,727 | — | — | 603,069 | — | plan? |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:12 pm EDT | Richard N. SpiveyDirector | 22,727 | — | — | 70,804 | — | plan? |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:11 pm EDT | Thomas WoiwodeDirector | 22,727 | — | — | 70,380 | — | plan? |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:09 pm EDT | Paul B ClevelandChief Executive Officer, Director | 22,727 | — | — | 22,727 | — | plan? |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:07 pm EDT | Steven Daniel SchwartzDirector | 22,727 | — | — | 398,991 | — | plan? |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:04 pm EDT | Patrick MachadoDirector | 22,727 | — | — | 68,182 | — | plan? |
| Apr 28, 2017 AForm 4 → | May 1, 8:20 pm EDT | Thomas WoiwodeDirector | 2,223 | — | — | 47,653 | — | plan? |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:34 pm EDT | Richard N. SpiveyDirector | 48,077 | — | — | 48,077 | — | plan? |
| Mar 31, 2017 AForm 4 → | Apr 3, 5:57 pm EDT | Thomas WoiwodeDirector | 3,704 | — | — | 45,430 | — | plan? |
| Mar 14, 2017 AForm 4 → | Mar 16, 7:19 pm EDT | Patrick MachadoDirector | 45,455 | — | — | 45,455 | — | plan? |
| Feb 28, 2017 AForm 4 → | Mar 2, 4:58 pm EST | Thomas WoiwodeDirector | 3,774 | — | — | 41,726 | — | plan? |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:47 pm EST | Amber SalzmanPresident and CEO, Director | 262,000 | — | — | 891,766 | — | plan? |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:43 pm EST | Leone D PattersonCFO | 80,000 | — | — | 180,000 | — | plan? |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:40 pm EST | Mehdi GasmiChief Science & Tech Officer | 125,000 | — | — | 289,535 | — | plan? |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:35 pm EST | Samuel B. BaroneSVP, Clinical Development | 58,000 | — | — | 172,335 | — | plan? |
| Jan 31, 2017 AForm 4 → | Feb 2, 4:41 pm EST | Thomas WoiwodeDirector | 3,449 | — | — | 37,952 | — | plan? |
| Dec 30, 2016 AForm 4 → | Jan 3, 2017, 5:27 pm EST | Thomas WoiwodeDirector | 3,449 | — | — | 34,503 | — | plan? |
| Nov 30, 2016 AForm 4 → | Dec 1, 6:05 pm EST | Thomas WoiwodeDirector | 3,509 | — | — | 31,054 | — | plan? |
| Oct 31, 2016 AForm 4 → | Nov 1, 6:48 pm EDT | Thomas WoiwodeDirector | 3,390 | — | — | 27,545 | — | plan? |
| Jun 17, 2016 AForm 4 → | Jun 21, 5:51 pm EDT | Samuel B. BaroneSVP, Clinical Development | 20,000 | — | — | 114,335 | — | plan? |
| Jun 15, 2016 AForm 4 → | Jun 16, 7:26 pm EDT | Leone D PattersonCFO | 100,000 | — | — | 100,000 | — | plan? |
| May 11, 2016 AForm 4 → | Jul 1, 6:18 pm EDT | Thomas WoiwodeDirector | 24,155 | — | — | 24,155 | — | plan? late |
| May 11, 2016 AForm 4 → | Jul 1, 6:16 pm EDT | Mitchell H. FinerDirector | 24,155 | — | — | 580,342 | — | plan? late |
| May 11, 2016 AForm 4 → | May 13, 5:52 pm EDT | Amber SalzmanPresident and COO, Director | 629,766 | — | — | 629,766 | — | plan? |
| Feb 29, 2016 AForm 4 → | Mar 2, 5:12 pm EST | Paul WachterDirector | 3,907 | — | — | 31,951 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:42 pm EST | John Peter McLaughlinDirector | 8,333 | — | — | 10,333 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:40 pm EST | Steven Daniel SchwartzDirector | 8,333 | — | — | 376,264 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:37 pm EST | Mark S. BlumenkranzDirector | 8,333 | — | — | 531,322 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:34 pm EST | Paul WachterDirector | 8,333 | — | — | 28,044 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:33 pm EST | Mehdi GasmiChief Scientific Officer | 125,000 | — | — | 161,803 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:31 pm EST | Roman G. RubioSVP, Translational Medicine | 50,000 | — | — | 165,650 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:30 pm EST | Samuel B. BaroneChief Medical Officer | 50,000 | — | — | 91,603 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:28 pm EST | Michael SwartzburgPrincipal Accounting Officer | 36,900 | — | — | 82,113 | — | plan? |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:26 pm EST | Shirley BraunVP, Human Resources | 116,900 | — | — | 161,140 | — | plan? |
| Jan 29, 2016 AForm 4 → | Feb 1, 5:46 pm EST | Paul WachterDirector | 3,334 | — | — | 19,711 | — | plan? |
| Dec 31, 2015 AForm 4 → | Jan 4, 2016, 6:12 pm EST | Paul WachterDirector | 2,101 | — | — | 16,377 | — | plan? |
| Nov 30, 2015 AForm 4 → | Dec 2, 4:39 pm EST | Paul WachterDirector | 1,909 | — | — | 14,276 | — | plan? |
| Oct 30, 2015 AForm 4 → | Nov 2, 4:51 pm EST | Paul WachterDirector | 2,373 | — | — | 12,367 | — | plan? |
| Sep 30, 2015 AForm 4 → | Oct 2, 5:45 pm EDT | Paul WachterDirector | 2,428 | — | — | 9,994 | — | plan? |
| Sep 21, 2015 AForm 4 → | Sep 23, 7:12 pm EDT | Shirley BraunVP, Human Resources | 3,500 | — | — | 44,240 | — | plan? |
| Sep 9, 2015 AForm 4 → | Sep 11, 4:48 pm EDT | Paul WachterDirector | 5,566 | — | — | 7,566 | — | plan? |
| Aug 21, 2015 AForm 4 → | Aug 25, 5:09 pm EDT | Hans HullChief Executive Officer | 117,590 | — | — | 137,210 | — | plan? |
| Aug 21, 2015 AForm 4 → | Aug 25, 5:07 pm EDT | Mehdi GasmiChief Scientific Officer | 29,160 | — | — | 36,160 | — | plan? |
| Aug 21, 2015 AForm 4 → | Aug 25, 5:05 pm EDT | Samuel B. BaroneChief Medical Officer | 33,960 | — | — | 40,960 | — | plan? |
| Aug 21, 2015 AForm 4 → | Aug 25, 5:03 pm EDT | Roman G. RubioSVP, Translational Medicine | 108,650 | — | — | 115,650 | — | plan? |
| Aug 21, 2015 AForm 4 → | Aug 25, 5:00 pm EDT | Linda BainChief Financial Officer | 32,930 | — | — | 41,930 | — | plan? |
| Jun 15, 2015 SForm 4 → | Jun 17, 8:33 pm EDT | Mehdi GasmiSVP,Pharmaceutical Development | 500 | $39.86 | $19,931 | 7,000 | −6.67% | plan? |
| Jun 15, 2015 MForm 4 → | Jun 17, 8:33 pm EDT | Mehdi GasmiSVP,Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? |
| Jun 15, 2015 SForm 4 → | Jun 17, 8:33 pm EDT | Paul WachterDirector | 1,192 | $39.86 | $47,516 | 37,161 | −3.11% | plan? |
| Jun 15, 2015 SForm 4 → | Jun 17, 8:33 pm EDT | Steven Daniel SchwartzDirector | 16,875 | $39.86 | $672,671 | 367,931 | −4.39% | plan? |
| Jun 12, 2015 MForm 4 → | Jun 16, 6:25 pm EDT | Hans HullSVP, Business Operations | 8,300 | $0.19 | $1,577 | 19,620 | — | plan? |
| Jun 12, 2015 SForm 4 → | Jun 15, 5:00 pm EDT | Linda BainChief Financial Officer | 3,500 | $39.94 | $139,795 | 9,000 | −28.0% | plan? |
| Jun 12, 2015 MForm 4 → | Jun 15, 5:00 pm EDT | Linda BainChief Financial Officer | 3,500 | $3.15 | $11,025 | 12,500 | — | plan? |
| Jun 11, 2015 SForm 4 → | Jun 15, 5:01 pm EDT | Mark S. BlumenkranzDirector | 1,900 | $39.97 | $75,939 | 522,989 | −0.36% | plan? |
| Jun 10, 2015 SForm 4 → | Jun 11, 6:21 pm EDT | Thomas W. ChalbergChief Executive Officer, Director | 25,000 | $38.05 | $951,194 | 258,988 | −8.80% | plan? |
| Jun 9, 2015 SForm 4 → | Jun 11, 6:21 pm EDT | Mark S. BlumenkranzDirector | 23,100 | $35.86 | $828,276 | 524,889 | −4.22% | plan? |
| Jun 8, 2015 SForm 4 → | Jun 10, 8:29 pm EDT | Paul WachterDirector | 1,192 | $38.64 | $46,061 | 38,353 | −3.01% | plan? |
| Jun 8, 2015 SForm 4 → | Jun 10, 8:28 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $38.64 | $19,321 | 7,000 | −6.67% | plan? |
| Jun 8, 2015 MForm 4 → | Jun 10, 8:28 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? |
| Jun 5, 2015 SForm 4 → | Jun 8, 5:20 pm EDT | Mark S. BlumenkranzDirector | 5,000 | $40.08 | $200,414 | 547,989 | −0.90% | plan? |
| Jun 4, 2015 SForm 4 → | Jun 5, 5:59 pm EDT | Hans HullSVP, Business Operations | 2,000 | $37.64 | $75,283 | 11,320 | −15.0% | plan? |
| Jun 4, 2015 MForm 4 → | Jun 5, 5:59 pm EDT | Hans HullSVP, Business Operations | 2,000 | $0.19 | $380 | 13,320 | — | plan? |
| Jun 1, 2015 SForm 4 → | Jun 2, 8:24 pm EDT | Paul WachterDirector | 1,192 | $36.23 | $43,191 | 39,545 | −2.93% | plan? |
| Jun 1, 2015 SForm 4 → | Jun 2, 8:24 pm EDT | Steven Daniel SchwartzDirector | 17,250 | $36.23 | $625,043 | 384,806 | −4.29% | plan? |
| May 28, 2015 SForm 4/A → | Jun 5, 8:00 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $38.02 | $19,009 | 7,000 | −6.67% | plan? |
| May 28, 2015 MForm 4/A → | Jun 5, 8:00 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? |
| May 28, 2015 SForm 4 → | May 29, 2:37 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $38.02 | $19,009 | 7,000 | −6.67% | plan? amended |
| May 28, 2015 MForm 4 → | May 29, 2:37 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? amended |
| May 26, 2015 SForm 4 → | May 27, 6:39 pm EDT | Paul WachterDirector | 1,192 | $36.94 | $44,037 | 40,737 | −2.84% | plan? |
| May 22, 2015 SForm 4 → | May 22, 7:21 pm EDT | Steven Daniel SchwartzDirector | 16,875 | $38.38 | $647,687 | 402,056 | −4.03% | plan? |
| May 21, 2015 SForm 4 → | May 22, 4:36 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $38.87 | $19,435 | 7,000 | −6.67% | plan? |
| May 21, 2015 MForm 4 → | May 22, 4:36 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? |
| May 19, 2015 SForm 4 → | May 21, 5:53 pm EDT | Mark S. BlumenkranzDirector | 3,000 | $36.91 | $110,734 | 10,531 | −22.2% | plan? |
| May 18, 2015 SForm 4 → | May 19, 6:24 pm EDT | Paul WachterDirector | 1,192 | $35.31 | $42,086 | 41,929 | −2.76% | plan? |
| May 15, 2015 SForm 4 → | May 18, 5:22 pm EDT | Mark S. BlumenkranzDirector | 22,500 | $35.49 | $798,553 | 552,989 | −3.91% | plan? |
| May 14, 2015 SForm 4 → | May 15, 5:47 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $35.31 | $17,656 | 7,000 | −6.67% | plan? |
| May 14, 2015 MForm 4 → | May 15, 5:47 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? |
| May 13, 2015 SForm 4 → | May 13, 7:16 pm EDT | Mark S. BlumenkranzDirector | 715 | $34.94 | $24,984 | 575,489 | −0.12% | plan? |
| May 13, 2015 SForm 4 → | May 13, 7:15 pm EDT | Linda BainChief Financial Officer | 285 | $34.94 | $9,959 | 9,000 | −3.07% | plan? |
| May 13, 2015 MForm 4 → | May 13, 7:15 pm EDT | Linda BainChief Financial Officer | 285 | $3.15 | $898 | 9,285 | — | plan? |
| May 11, 2015 SForm 4 → | May 12, 5:05 pm EDT | Paul WachterDirector | 1,192 | $33.38 | $39,792 | 43,121 | −2.69% | plan? |
| May 11, 2015 SForm 4 → | May 12, 5:03 pm EDT | Linda BainChief Financial Officer | 715 | $34.91 | $24,964 | 9,000 | −7.36% | plan? |
| May 11, 2015 MForm 4 → | May 12, 5:03 pm EDT | Linda BainChief Financial Officer | 715 | $3.15 | $2,252 | 9,715 | — | plan? |
| May 11, 2015 SForm 4 → | May 12, 5:00 pm EDT | Mark S. BlumenkranzDirector | 1,785 | $34.91 | $62,323 | 576,204 | −0.31% | plan? |
| May 8, 2015 SForm 4 → | May 11, 5:00 pm EDT | Steven Daniel SchwartzDirector | 17,250 | $33.05 | $570,092 | 418,931 | −3.95% | plan? |
| May 7, 2015 SForm 4 → | May 8, 7:09 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $33.28 | $16,638 | 7,000 | −6.67% | plan? |
| May 7, 2015 MForm 4 → | May 8, 7:09 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | $2.75 | $1,375 | 7,500 | — | plan? |
| May 5, 2015 SForm 4 → | May 7, 4:16 pm EDT | Thomas W. ChalbergChief Executive Officer, Director | 25,000 | $30.00 | $750,093 | 283,988 | −8.09% | plan? |
| May 4, 2015 SForm 4 → | May 6, 4:06 pm EDT | Hans HullSVP, Business Operations | 5,000 | $30.87 | $154,349 | 11,320 | −30.6% | plan? |
| May 4, 2015 MForm 4 → | May 6, 4:06 pm EDT | Hans HullSVP, Business Operations | 5,000 | $0.19 | $950 | 16,320 | — | plan? |
| May 4, 2015 SForm 4 → | May 6, 4:06 pm EDT | Linda BainChief Financial Officer | 2,500 | $31.59 | $78,972 | 9,000 | −21.7% | plan? |
| May 4, 2015 MForm 4 → | May 6, 4:06 pm EDT | Linda BainChief Financial Officer | 2,500 | $3.15 | $7,875 | 11,500 | — | plan? |
| May 4, 2015 SForm 4 → | May 6, 4:05 pm EDT | Paul WachterDirector | 1,192 | $30.87 | $36,797 | 44,313 | −2.62% | plan? |
| May 1, 2015 SForm 4 → | May 5, 4:06 pm EDT | Mark S. BlumenkranzDirector | 20,000 | $32.37 | $647,306 | 577,989 | −3.34% | plan? |
| Apr 28, 2015 SForm 4 → | Apr 30, 6:51 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | $35.67 | $35,667 | 7,000 | −12.5% | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2019 AForm 4 → | Feb 19, 4:17 pm EST | Jennifer C. ChengGeneral Counsel | 80,000 | — | — | 80,000 | — | |
| Feb 14, 2019 AForm 4 → | Feb 19, 4:17 pm EST | Mehdi GasmiPresident and CSO | 225,000 | — | — | 225,000 | — | |
| Feb 14, 2019 AForm 4 → | Feb 19, 4:15 pm EST | Leone D PattersonCEO, CFO and Director, Director | 800,000 | — | — | 800,000 | — | |
| Oct 18, 2018 AForm 4 → | Oct 22, 4:17 pm EDT | Leone D PattersonPresident, CEO and CFO | 150,000 | — | — | 150,000 | — | |
| May 31, 2018 AForm 4 → | Jun 15, 4:38 pm EDT | Patrick MachadoDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:30 pm EDT | Richard N. SpiveyDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:28 pm EDT | Eric G CarterDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:27 pm EDT | Thomas WoiwodeDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:26 pm EDT | Mitchell H. FinerDirector | 35,000 | — | — | 35,000 | — | late |
| May 31, 2018 AForm 4 → | Jun 15, 4:25 pm EDT | Paul B ClevelandDirector | 35,000 | — | — | 35,000 | — | late |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:19 pm EST | Patrick MachadoDirector | 10,000 | — | — | 10,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:18 pm EST | Jennifer C. ChengGeneral Counsel | 114,000 | — | — | 114,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:17 pm EST | Leone D PattersonChief Financial Officer | 160,000 | — | — | 160,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:17 pm EST | Mehdi GasmiChief Science & Tech Officer | 160,000 | — | — | 160,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:16 pm EST | Athena CountouriotisSVP, Chief Medical Officer | 160,000 | — | — | 160,000 | — | |
| Feb 15, 2018 AForm 4 → | Feb 20, 7:15 pm EST | Amber SalzmanPresident and CEO, Director | 478,000 | — | — | 478,000 | — | |
| Sep 7, 2017 AForm 4 → | Sep 8, 6:40 pm EDT | Eric G CarterDirector | 69,000 | — | — | 69,000 | — | |
| Jun 19, 2017 AForm 4 → | Jun 21, 6:11 pm EDT | Athena CountouriotisSVP, Chief Medical Officer | 213,000 | — | — | 213,000 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:13 pm EDT | Mitchell H. FinerDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:12 pm EDT | Richard N. SpiveyDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:11 pm EDT | Thomas WoiwodeDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:09 pm EDT | Paul B ClevelandChief Executive Officer, Director | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:07 pm EDT | Steven Daniel SchwartzDirector | 33,602 | — | — | 33,602 | — | |
| Jun 12, 2017 AForm 4 → | Jun 14, 7:04 pm EDT | Patrick MachadoDirector | 33,602 | — | — | 33,602 | — | |
| Apr 19, 2017 AForm 4 → | Apr 21, 4:34 pm EDT | Richard N. SpiveyDirector | 69,061 | — | — | 69,061 | — | |
| Mar 14, 2017 AForm 4 → | Mar 16, 7:19 pm EDT | Patrick MachadoDirector | 64,767 | — | — | 64,767 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:47 pm EST | Amber SalzmanPresident and CEO, Director | 378,000 | — | — | 378,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:43 pm EST | Leone D PattersonCFO | 116,000 | — | — | 116,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:40 pm EST | Mehdi GasmiChief Science & Tech Officer | 181,000 | — | — | 181,000 | — | |
| Feb 9, 2017 AForm 4 → | Feb 13, 5:35 pm EST | Samuel B. BaroneSVP, Clinical Development | 84,000 | — | — | 84,000 | — | |
| Jun 17, 2016 AForm 4 → | Jun 21, 5:51 pm EDT | Samuel B. BaroneSVP, Clinical Development | 50,000 | — | — | 50,000 | — | |
| Jun 15, 2016 AForm 4 → | Jun 16, 7:26 pm EDT | Leone D PattersonCFO | 200,000 | — | — | 200,000 | — | |
| May 11, 2016 AForm 4 → | Jul 1, 6:18 pm EDT | Thomas WoiwodeDirector | 44,248 | — | — | 44,248 | — | late |
| May 11, 2016 AForm 4 → | Jul 1, 6:16 pm EDT | Mitchell H. FinerDirector | 44,248 | — | — | 44,248 | — | late |
| May 11, 2016 AForm 4 → | May 13, 5:52 pm EDT | Amber SalzmanPresident and COO, Director | 595,890 | — | — | 218,000 | — | |
| May 11, 2016 AForm 4 → | May 13, 5:48 pm EDT | Carlo RussoEVP and Chief Medical Officer | 781,991 | — | — | 66,000 | — | |
| May 11, 2016 AForm 4 → | May 13, 5:40 pm EDT | Paul B ClevelandChief Executive Officer, Director | 381,000 | — | — | 381,000 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:42 pm EST | John Peter McLaughlinDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:40 pm EST | Steven Daniel SchwartzDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:37 pm EST | Mark S. BlumenkranzDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:34 pm EST | Paul WachterDirector | 11,905 | — | — | 11,905 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:33 pm EST | Mehdi GasmiChief Scientific Officer | 188,000 | — | — | 188,000 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:31 pm EST | Roman G. RubioSVP, Translational Medicine | 75,000 | — | — | 75,000 | — | |
| Feb 12, 2016 AForm 4 → | Feb 17, 5:30 pm EST | Samuel B. BaroneChief Medical Officer | 75,000 | — | — | 75,000 | — | |
| Dec 9, 2015 AForm 4 → | Dec 11, 4:59 pm EST | Paul B ClevelandPresident and CEO, Director | 910,000 | — | — | 910,000 | — | |
| Jun 15, 2015 MForm 4 → | Jun 17, 8:33 pm EDT | Mehdi GasmiSVP,Pharmaceutical Development | 500 | — | — | 95,000 | — | |
| Jun 12, 2015 MForm 4 → | Jun 16, 6:25 pm EDT | Hans HullSVP, Business Operations | 8,300 | — | — | 12,200 | — | |
| Jun 12, 2015 MForm 4 → | Jun 15, 5:00 pm EDT | Linda BainChief Financial Officer | 3,500 | — | — | 233,000 | — | |
| Jun 8, 2015 MForm 4 → | Jun 10, 8:28 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 95,500 | — | |
| Jun 4, 2015 MForm 4 → | Jun 5, 5:59 pm EDT | Hans HullSVP, Business Operations | 2,000 | — | — | 20,500 | — | |
| May 28, 2015 MForm 4/A → | Jun 5, 8:00 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 96,000 | — | |
| May 28, 2015 MForm 4 → | May 29, 2:37 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 96,000 | — | amended |
| May 21, 2015 MForm 4 → | May 22, 4:36 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 96,500 | — | |
| May 14, 2015 MForm 4 → | May 15, 5:47 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 97,000 | — | |
| May 13, 2015 MForm 4 → | May 13, 7:15 pm EDT | Linda BainChief Financial Officer | 285 | — | — | 236,500 | — | |
| May 11, 2015 MForm 4 → | May 12, 5:03 pm EDT | Linda BainChief Financial Officer | 715 | — | — | 236,785 | — | |
| May 7, 2015 MForm 4 → | May 8, 7:09 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 500 | — | — | 97,500 | — | |
| May 4, 2015 MForm 4 → | May 6, 4:06 pm EDT | Hans HullSVP, Business Operations | 5,000 | — | — | 22,500 | — | |
| May 4, 2015 MForm 4 → | May 6, 4:06 pm EDT | Linda BainChief Financial Officer | 2,500 | — | — | 237,500 | — | |
| Apr 28, 2015 MForm 4 → | Apr 30, 6:51 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | — | — | 98,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:02 pm EDT | Paul WachterDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:02 pm EDT | Steven Daniel SchwartzDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:01 pm EDT | Roman G. RubioSVP, Translational Medicine | 20,000 | — | — | 20,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 5:00 pm EDT | John Peter McLaughlinDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:59 pm EDT | Hans HullSVP, Business Operations | 23,000 | — | — | 23,000 | — | |
| Apr 21, 2015 AMForm 4 → | Apr 23, 4:58 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 21,000 | — | — | 20,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:57 pm EDT | Thomas W. ChalbergChief Executive Officer, Director | 67,000 | — | — | 67,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:56 pm EDT | Mark S. BlumenkranzDirector | 7,000 | — | — | 7,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:55 pm EDT | Samuel B. BaroneChief Medical Officer | 20,000 | — | — | 20,000 | — | |
| Apr 21, 2015 AForm 4 → | Apr 23, 4:53 pm EDT | Linda BainChief Financial Officer | 25,000 | — | — | 25,000 | — | |
| Apr 14, 2015 MForm 4 → | Apr 15, 5:24 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 1,000 | — | — | 100,000 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:32 pm EDT | Hans HullSVP, Business Operations | 27,500 | — | — | 27,500 | — | |
| Apr 7, 2015 MForm 4 → | Apr 8, 4:29 pm EDT | Mehdi GasmiVP, Pharmaceutical Development | 9,000 | — | — | 101,000 | — | |
| Dec 12, 2014 MForm 4 → | Jan 14, 2015, 5:43 pm EST | Thomas W. ChalbergChief Executive Officer, Director | 413 | — | — | 159,587 | — | late |